Bristol Myers Squibb and BioNTech report positive Phase 2 pumitamig data in lung cancer
FROM THE WIRE · FINANCE.YAHOO.COM
Bristol-Myers Squibb (NYSE:BMY) and BioNTech reported positive Phase 2 data for pumitamig in metastatic non-small cell lung cancer. The bispecific immunomodulator pumitamig, targeting PD-L1 and VEGF-A, showed strong antitumor activity with a manageable safety profile. This first…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishPositive clinical data on a late-stage drug can support sentiment toward a large pharmaceutical company.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Pumitamig, a bispecific targeting PD-L1 and VEGF-A, showed strong antitumor activity.
- 02The safety profile is manageable according to the Phase 2 data in metastatic non-small cell lung cancer.
- 03The data cover difficult lung cancer subgroups and will inform further development plans.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets